Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 3
1949 1
1950 6
1951 2
1952 3
1953 3
1954 2
1955 2
1956 1
1958 1
1959 1
1960 1
1964 1
1968 1
1971 1
1973 3
1976 1
1978 2
1979 1
1980 2
1987 1
1989 5
1990 2
1991 5
1992 15
1993 12
1994 13
1995 18
1996 15
1997 13
1998 17
1999 12
2000 17
2001 18
2002 17
2003 10
2004 10
2005 18
2006 20
2007 27
2008 16
2009 19
2010 19
2011 30
2012 48
2013 37
2014 39
2015 51
2016 40
2017 47
2018 51
2019 60
2020 72
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

757 results
Results by year
Filters applied: . Clear all
Page 1
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: porta c. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Targeting PI3K/Akt/mTOR Signaling in Cancer.
Porta C, Paglino C, Mosca A. Porta C, et al. Front Oncol. 2014 Apr 14;4:64. doi: 10.3389/fonc.2014.00064. eCollection 2014. Front Oncol. 2014. PMID: 24782981 Free PMC article. Review.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. Among authors: porta c. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Macrophage polarization in pathology.
Sica A, Erreni M, Allavena P, Porta C. Sica A, et al. Among authors: porta c. Cell Mol Life Sci. 2015 Nov;72(21):4111-26. doi: 10.1007/s00018-015-1995-y. Epub 2015 Jul 26. Cell Mol Life Sci. 2015. PMID: 26210152 Review.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Rini BI, et al. Among authors: porta c. Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9. Lancet. 2019. PMID: 31079938 Clinical Trial.
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Escudier B, et al. Among authors: porta c. Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056. Ann Oncol. 2019. PMID: 30788497 Free article. No abstract available.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: porta c. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
757 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page